Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus RESPORAL.
CEFOBID vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
2 mg orally twice daily
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic